<DOC>
	<DOCNO>NCT02421068</DOCNO>
	<brief_summary>This study provide information pharmacokinetics , safety effectiveness -- label drug use critically ill premature infant : doxapram , fentanyl , midazolam , paracetamol , phenobarbital , sildenafil , levetiracetam , ibuprofen fluconazole . PK/PD analysis NONMEM ( non-linear mixed effect model ) result ( adapt ) dosage guideline , thus contribute towards improvement quality care cost efficiency . Furthermore development Dried Blood Spot ( DBS ) analysis investigate drug minimally invasive method conventional patient care perform pharmacological study child . The adapted dosage guideline implement directly clinical practice collaboration NKFK . Therefore study design observational multicenter study able collect sufficient data drug interest .</brief_summary>
	<brief_title>Population PK/PD Off Label Drugs Premature Neonates</brief_title>
	<detailed_description>BACKGROUND Approximately 60 % drug use -- label critically ill neonate Neonatal Intensive Care Units ( NICU ) . This even true pre -- term born neonate pharmacokinetics agent may different due immature elimination pathway . The lack sufficient data efficacy safety many drug make difficult evidence base dose guideline agent . Therefore urge drug research population great importance . The pharmacokinetic ( PK ) pharmacodynamic ( PD ) characteristic drug premature infant different characteristic find term neonate , old child adult . These difference cause among others different body composition , immaturity renal excretion system , metabolic pathway liver organ function well immature drug receptor transporter . After birth , rapid development many function , necessitate frequent adaptation dosage guideline first week life . Besides age size , co -- morbidity , co -- administration drug genetic heterogeneity may contribute extensive inter -- individual variability pharmacokinetics pharmacodynamics premature infant . There critical lack evidence -- base data drug dosing ( extremely ) preterm neonate . OBJECTIVE Recently , population PK/PD model simulation study enable development evidence -- base individualized dosing scheme child limit number subject , thus improve drug safety efficacy . The application PK/PD model critically ill population premature infant , high variability pharmacokinetics drug , great lack adequate data underscore optimal dosage , contribute development rational , individualize safe dosing regimen . This study provide information pharmacokinetics , safety effectiveness -- label drug use critically ill premature infant : doxapram , fentanyl , midazolam , paracetamol , phenobarbital , sildenafil , levetiracetam , ibuprofen fluconazole ( studied PK ) . PK/PD analysis result ( adapt ) dosage guideline , thus contribute towards improvement quality care cost efficiency . Furthermore development Dried Blood Spot ( DBS ) analysis investigate drug minimally invasive method conventional patient care perform pharmacological study child . The adapted dosage guideline implement directly clinical practice collaboration NKFK . Therefore study design observational multicenter study able collect sufficient data drug interest . DESIGN This prospective observational multicenter study pharmacokinetics pharmacodynamics paracetamol , fentanyl , midazolam , phenobarbital , doxapram , levetiracetam , sildenafil , ibuprofen fluconazole routinely administer preterm infant accord standard protocol . The treatment regimen leave discretion treat physician accordance current guideline . During study limit number additional blood sample draw participant pharmacokinetic analysis , never exceed 3 % total blood volume four -- week period 1 % single time . It standard care Netherlands premature bear infant 32 week get see paediatrician age two year check growth development . The visit day care clinic hospital admission birth , enable u collect qualitative data growth physiological development well psychological neurodevelopmental standardise tests.The collect data enables u gain good description subject study determine safety study drug . POPULATION All preterm infant bear gestational age &lt; 32 week admit one participate NICUs eligible inclusion . The participate department level III Neonatal Intensive Care Units . Three situate academic hospital ( Rotterdam , Nijmegen Maastricht ) one non -- academic hospital ( Veldhoven ) . Patients admit 4 NICUs consist inborn outborn neonate different gestational age ( 24 -- 42 week ) . All admit patient need intensive high care treatment . Most patient admit first postnatal day , sometimes refer old post natal age ( &lt; 14 day ) NICU . OUTCOME Primary study parameters/outcome study : 1 ) Pharmacokinetic endpoint 9 drug clearance en volume distribution . Secondary study parameters/outcome study ( applicable ) : Pharmacodynamics paracetamol , fentanyl , midazolam , phenobarbital , doxapram , levetiracetam sildenafil explore included preterm neonate . Fluconazole study pharmacokinetics . Drug specific effect drug ( e.g . pain score morphine , blood pressure dopamine ) well side effect short term effect morbidity outcome analyze . Additional pharmacodynamic endpoint 7 PK/PD study drug drug target concentration drug relate desired effect . The parameter measure effect drug : 1 . Fentanyl paracetamol , use analgetics ; clinical endpoint pain relief , routinely measure validated COMFORTneo scale NRS ( numeric rating scale ) scale . 2 . Midazolam , phenobarbital levetiracetam , use anticonvulsive drugs; clinical endpoint control convulsion , measure Cerebral Function Monitoring use amplitude -- integrated EEG ( aEEG ) . 3 . Midazolam fentanyl , use sedative drug endotracheal intubation; clinical endpoint intubation readiness score ( IRS ) qualitative intubation score sedation score . 4 . Midazolam fentanyl , use sedative drug nursing care measure COMFORTneo scale . 5 . Doxapram , use treatment neonatal apnea ; clinical endpoint control neonatal apnea endotracheal intubation case failure . The first endpoint measure modern monitoring technology , central post -- monitoring data store initiation treatment reveal effect doxapram reduction elimination apnea . 6 . Sildenafil , treatment PH ( pulmonary hypertension ) ; clinical endpoint level ventilatory support , oxygen need ( repetitive oxygenation index analysis ) BPD ( broncho pulmonary dysplasia ) development . 7 . Ibuprofen use close patent ductus arteriosus ( PDA ) different dosage , orally intravenously recruit site . Endpoints measure cardiac ultrasound : ductus closure ( yes/no ) , ductal diameter LA/AO ratio Inter -- intra -- patient variability PD PK parameter drug investigate . Parameters effect variability identify . Tertiary outcome : 1 . Development minimally invasive Dried Blood Spot analysis method perform future pharmacokinetic study neonate . The measured concentration drug dry blood spot sample compare concentration blood sample vial , current validated standard method . The validity DBS method endpoint . 2 . Influence specific polymorphism involve metabolism investigate drug .</detailed_description>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Phenobarbital</mesh_term>
	<criteria>prescription one seven drug interest parental inform consent none</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>32 Weeks</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Paracetamol</keyword>
	<keyword>Fentanyl</keyword>
	<keyword>Phenobarbital</keyword>
	<keyword>Doxapram</keyword>
	<keyword>Midazolam</keyword>
	<keyword>Sildenafil</keyword>
	<keyword>Levetiracetam</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacology</keyword>
	<keyword>Fluconazole</keyword>
	<keyword>Ibuprofen</keyword>
</DOC>